ARTICLE | Company News
Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire Nanobodies company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) for €45 per share in cash, or about €3.9 billion ($4.84 billion). The price is a 21% premium to Ablynx's close of €37.12 on Friday, before the deal was announced, and a 48% premium to the €30.50 per share offered by Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) in its most recent unsolicited offer (see BioCentury Extra, Jan. 8).
In a statement Monday, Novo said it will not make a revised bid for Ablynx...
BCIQ Target Profiles